Search

Your search keyword '"Paolini, J."' showing total 425 results
Start Over Author "Paolini, J."
425 results on '"Paolini, J."'

1. OP0036 EFFICACY, SAFETY, AND PHARMACOKINETICS OF ANTI-CD40 ANTIBODY ABIPRUBART (KPL-404) IN PATIENTS WITH RHEUMATOID ARTHRITIS: A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED 12-WEEK-TREATMENT PROOF-OF-CONCEPT STUDY

Author

Jenkins, E., primary, Louw, I., additional, Balog, A., additional, Van Duuren, E., additional, Horowitz, D. L., additional, Jaworski, J., additional, Kivitz, A., additional, Ujfalussy, I., additional, Pirello, J., additional, Tessari, E., additional, Wang, S., additional, and Paolini, J. F., additional

Published
2024
Full Text
View/download PDF

5. 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study

Author

Hecht JR, Mitchell EP, Yoshino T, Welslau M, Lin X, Chow Maneval E, Paolini J, Lechuga MJ, and Kretzschmar A

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

J Randolph Hecht,1 Edith P Mitchell,2 Takayuki Yoshino,3 Manfred Welslau,4 Xun Lin,5 Edna Chow Maneval,6 Jolanda Paolini,7 Maria Jose Lechuga,7 Albrecht Kretzschmar8 1David Geffen School of Medicine at UCLA, Santa Monica, CA, 2Kimmel Cancer Center of Thomas Jefferson University, Philadelphia, PA, USA; 3National Cancer Center Hospital East, Chiba, Japan; 4Onkologische Praxis Klausmann/Welslau, Aschaffenburg, Germany; 5Pfizer Oncology, La Jolla, 6Seragon Pharmaceuticals, San Diego, CA, USA; 7Pfizer Oncology, Milan, Italy; 8Klinikum St Georg, Leipzig, Germany Background: Sunitinib is an oral inhibitor of tyrosine kinase receptors implicated in tumor proliferation, angiogenesis, and metastasis. In this randomized, multicenter, open-label Phase IIb study, sunitinib plus mFOLFOX6 (oxaliplatin plus leucovorin plus 5-fluorouracil) was compared with bevacizumab plus mFOLFOX6 as first-line therapy in patients with metastatic colorectal cancer. Methods: Patients were stratified by performance status, baseline lactate dehydrogenase level, and prior adjuvant treatment, and randomized 1:1 to receive sunitinib 37.5 mg/day for 4 weeks on and 2 weeks off plus mFOLFOX6 every 2 weeks or bevacizumab 5 mg/kg every 2 weeks plus mFOLFOX6 every 2 weeks. The primary endpoint was progression-free survival. Secondary endpoints included objective response rate, overall survival, safety, and quality of life. Results: Enrollment was closed early following accrual of 191 patients, based on an interim analysis showing an inferior trend in the primary progression-free survival efficacy endpoint for sunitinib. Ninety-six patients were randomized to sunitinib plus mFOLFOX6 and 95 to bevacizumab plus mFOLFOX6. Median progression-free survival was 9.3 months and 15.4 months, respectively, but the objective response rate was similar between the study arms. Median overall survival was 23.7 months and 34.1 months, respectively. Dose reductions and interruptions were more common with sunitinib. Hematologic toxicity was more common in the sunitinib arm. Conclusion: While the results of the sunitinib arm are comparable with those of previously reported FOLFOX combinations, the sunitinib-based combination was associated with more toxicity than that observed with bevacizumab and mFOLFOX6. The bevacizumab arm had an unexpectedly good outcome, and was much better than that seen in the Phase III trials. Combination therapy with sunitinib plus mFOLFOX6 is not recommended for patients with metastatic colorectal cancer. Keywords: antiangiogenesis, bevacizumab, combination therapy, metastatic colorectal cancer, oxaliplatin, sunitinib

Published
2015

6. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study

Author

De Luca G., Cavalli G., Campochiaro C., Della-Torre E., Angelillo P., Tomelleri A., Boffini N., Tentori S., Mette F., Farina N., Rovere-Querini P., Ruggeri A., D'Aliberti T., Scarpellini P., Landoni G., De Cobelli F., Paolini J. F., Zangrillo A., Tresoldi M., Trapnell B. C., Ciceri F., Dagna L., DE LUCA , GIACOMO, De Luca, G., Cavalli, G., Campochiaro, C., Della-Torre, E., Angelillo, P., Tomelleri, A., Boffini, N., Tentori, S., Mette, F., Farina, N., Rovere-Querini, P., Ruggeri, A., D'Aliberti, T., Scarpellini, P., Landoni, G., De Cobelli, F., Paolini, J. F., Zangrillo, A., Tresoldi, M., Trapnell, B. C., Ciceri, F., Dagna, L., and DE LUCA, Giacomo

Subjects
Mechanical ventilation, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), business.industry, medicine.medical_treatment, Immunology, medicine.disease, Article, Blockade, Single centre, Pneumonia, Mavrilimumab, Rheumatology, Internal medicine, medicine, Immunology and Allergy, Prospective cohort study, Adverse effect, business
Abstract

Summary Background Mortality in patients with COVID-19 pneumonia and systemic hyperinflammation is high. We aimed to examine whether mavrilimumab, an anti-granulocyte–macrophage colony-stimulating factor receptor-α monoclonal antibody, added to standard management, improves clinical outcomes in patients with COVID-19 pneumonia and systemic hyperinflammation. Methods This single-centre prospective cohort study included patients aged 18 years or older who were admitted to San Raffaele Hospital (Milan, Italy) with severe COVID-19 pneumonia, hypoxia, and systemic hyperinflammation. Patients received a single intravenous dose (6 mg/kg) of mavrilimumab added to standard care given by the hospital at the time. The control group consisted of contemporaneous patients with similar baseline characteristics who received standard care at the same hospital. The main outcome was time to clinical improvement (defined as improvement of two or more points on the seven-point ordinal scale of clinical status). Other outcomes included proportion of patients achieving clinical improvement, survival, mechanical ventilation-free survival, and time to fever resolution. Adverse events were monitored daily. Findings Between March 17 and April 15, 2020, 13 non-mechanically ventilated patients (median age 57 years [IQR 52–58], 12 [92%] men) received mavrilimumab and 26 patients (median age 60 [IQR 53–67], 17 [65%] men) in the control group received standard care. During the 28-day follow-up, no patients in the mavrilimumab group died, and seven (27%) patients in the control group died (p=0·086). At day 28, all patients in the mavrilimumab group and 17 (65%) patients in the control group showed clinical improvement (p=0·030), with earlier improvement in the mavrilimumab than in the control group (mean time to improvement 8 days [IQR 5 to 11] vs 19 days [11 to >28], p=0·0001). By day 28, one (8%) patient in the mavrilimumab group progressed to mechanical ventilation compared with nine (35%) patients in the control group who progressed to mechanical ventilation or died (p=0·14). By day 14, fever resolved in ten (91%) of 11 febrile patients in the mavrilimumab group, compared with 11 (61%) of 18 febrile patients in the control group (p=0·18); fever resolution was faster in mavrilimumab recipients versus controls (median time to resolution 1 day [IQR 1 to 2] vs 7 days [3 to >14], p=0·0093). Mavrilimumab was well tolerated, with no infusion reactions. Three (12%) patients in the control group developed infectious complications. Interpretation Mavrilimumab treatment was associated with improved clinical outcomes compared with standard care in non-mechanically ventilated patients with severe COVID-19 pneumonia and systemic hyperinflammation. Treatment was well tolerated. Confirmation of efficacy requires controlled testing. Funding IRCCS San Raffaele Scientific Institute.

Published
2020

17. AB0379 DOSE-DEPENDENT SUPPRESSION OF T CELL-DEPENDENT ANTIBODY RESPONSE IN HEALTHY VOLUNTEERS BY KPL-404, AN ANTI-CD40 MONOCLONAL ANTIBODY, SUPPORTS CHRONIC DOSING STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS

Author

Papandrikopoulou, A., primary, Burmester, G. R., additional, Fang, F., additional, Kivitz, A., additional, Njenga, M., additional, Pano, A., additional, Pitzalis, C., additional, Samant, M., additional, Schmitz, S., additional, Spiers, M., additional, Tessari, E., additional, Ziemniak, J., additional, and Paolini, J. F., additional

Published
2022
Full Text
View/download PDF

18. POS0251 TRANSCRIPTOMIC CHANGES INDUCED BY MAVRILIMUMAB VERSUS TOCILIZUMAB IN EX-VIVO CULTURED ARTERIES FROM PATIENTS WITH GIANT-CELL ARTERITIS

Author

Corbera-Bellalta, M., primary, Kamberovic, F., additional, Araujo, F., additional, Alba-Rovira, R., additional, Espigol-Frigole, G., additional, Alba, M., additional, Prieto-González, S., additional, Hernández-Rodríguez, J., additional, Pérez-Galán, P., additional, Bondensgaard, K., additional, Paolini, J. F., additional, and Cid, M. C., additional

Published
2022
Full Text
View/download PDF

20. The Role of NLRP3 Inflammasome in Pericarditis: Potential for Therapeutic Approaches

Author

Mauro A. G., Bonaventura A., Vecchie A., Mezzaroma E., Carbone S., Narayan P., Potere N., Cannata A., Paolini J. F., Bussani R., Montecucco F., Sinagra G., Van Tassel B. W., Abbate A., Toldo S., Mauro, A. G., Bonaventura, A., Vecchie, A., Mezzaroma, E., Carbone, S., Narayan, P., Potere, N., Cannata, A., Paolini, J. F., Bussani, R., Montecucco, F., Sinagra, G., Van Tassel, B. W., Abbate, A., and Toldo, S.

Subjects
IL-1 trap, anakinra, colchicine, IL-1α, IL-1β, NLRP3 inflammasome, pericarditis
Abstract

Human samples of patients with chronic pericarditis and appropriate control subjects were stained for the inflammasome components. A mouse model of pericarditis was developed through the intrapericardial injection of zymosan A. Different inflammasome blockers were tested in the mouse model. Patients with pericarditis presented an intensification of the inflammasome activation compared with control subjects. The experimental model showed the pathological features of pericarditis. Among inflammasome blockers, NLRP3 inflammasome inhibitor, anakinra, and interleukin-1 trap were found to significantly improve pericardial alterations. Colchicine partially improved the pericardial inflammation. An intense activation of the inflammasome in pericarditis was demonstrated both in humans and in mice.

Published
2021

22. RESONANCE Registry: rationale and design of the retrospective and prospective longitudinal, observational registry in pediatric and adult patients with recurrent pericarditis

Author

Reid, A, primary, Klein, A, additional, Lin, D, additional, Abbate, A, additional, Luis, S A, additional, Petersen, J, additional, Portman, M, additional, Winnowski, D, additional, Malinowski, A, additional, Marden, L, additional, Paolini, J F, additional, and Martin, D, additional

Published
2021
Full Text
View/download PDF

25. PRO69 Real-World Treatments and Health-Related Quality of Life in Patients with Prurigo Nodularis in the Lotus PN Observational Trial

Author

Stander, S., primary, Lim-Watson, M., additional, Berger, T., additional, Silverberg, J., additional, Weisshaar, E., additional, Friedman, A., additional, Szepietowski, J.C., additional, Kim, B., additional, Pariser, D., additional, Ekanayake-Bohlig, S., additional, Metz, M., additional, Papandrikopoulou, A., additional, Jiang, G.L., additional, Paolini, J., additional, Martin, D., additional, and Yosipovitch, G., additional

Published
2021
Full Text
View/download PDF

26. LB0001 MAVRILIMUMAB IMPROVES OUTCOMES IN PHASE 2 TRIAL IN NON-MECHANICALLY-VENTILATED PATIENTS WITH SEVERE COVID-19 PNEUMONIA AND SYSTEMIC HYPERINFLAMMATION

Author

Pupim, L., primary, Wang, T. S., additional, Hudock, K., additional, Denson, J., additional, Fourie, N., additional, Hercilla Vasquez, L., additional, Luz, K., additional, Madjid, M., additional, Mcharry, K., additional, Saraiva, J. F., additional, Tobar, E., additional, Zhou, T., additional, Samant, M., additional, Pirrello, J., additional, Fang, F., additional, Paolini, J. F., additional, Pano, A., additional, and Trapnell, B. C., additional

Published
2021
Full Text
View/download PDF

28. AB0370 UTILITY OF CRP AND ESR IN THE DIAGNOSIS OF GIANT CELL ARTERITIS RELAPSE IN A PHASE 2 TRIAL OF MAVRILIMUMAB

Author

Unizony, S., primary, Cid, M. C., additional, Brouwer, E., additional, Dagna, L., additional, Dasgupta, B., additional, Hellmich, B., additional, Molloy, E., additional, Salvarani, C., additional, Trapnell, B. C., additional, Warrington, K. J., additional, Wicks, I., additional, Samant, M., additional, Zhou, T., additional, Pupim, L., additional, and Paolini, J. F., additional

Published
2021
Full Text
View/download PDF

29. Corrigendum to 'Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischaemia' [Eur J Vasc Endovasc Surg 58 (1S) (2019) 1–109>] (European Journal of Vascular & Endovascular Surgery (2019) 58(1S) (S1–S109.e33), (S1078588419303806), (10.1016/j.ejvs.2019.05.006))

Author

Conte M. S., Bradbury A. W., Kolh P., White J. V., Dick F., Fitridge R., Mills J. L., Ricco J. -B., Suresh K. R., Murad M. H., Aboyans V., Aksoy M., Alexandrescu V. -A., Armstrong D., Azuma N., Belch J., Bergoeing M., Bjorck M., Chakfe N., Cheng S., Dawson J., Debus E. S., Dueck A., Duval S., Eckstein H. H., Ferraresi R., Gambhir R., Gargiulo M., Geraghty P., Goode S., Gray B., Guo W., Gupta P. C., Hinchliffe R., Jetty P., Komori K., Lavery L., Liang W., Lookstein R., Menard M., Misra S., Miyata T., Moneta G., Munoa Prado J. A., Munoz A., Paolini J. E., Patel M., Pomposelli F., Powell R., Robless P., Rogers L., Schanzer A., Schneider P., Taylor S., De Ceniga M. V., Veller M., Vermassen F., Wang J., Wang S., Conte M.S., Bradbury A.W., Kolh P., White J.V., Dick F., Fitridge R., Mills J.L., Ricco J.-B., Suresh K.R., Murad M.H., Aboyans V., Aksoy M., Alexandrescu V.-A., Armstrong D., Azuma N., Belch J., Bergoeing M., Bjorck M., Chakfe N., Cheng S., Dawson J., Debus E.S., Dueck A., Duval S., Eckstein H.H., Ferraresi R., Gambhir R., Gargiulo M., Geraghty P., Goode S., Gray B., Guo W., Gupta P.C., Hinchliffe R., Jetty P., Komori K., Lavery L., Liang W., Lookstein R., Menard M., Misra S., Miyata T., Moneta G., Munoa Prado J.A., Munoz A., Paolini J.E., Patel M., Pomposelli F., Powell R., Robless P., Rogers L., Schanzer A., Schneider P., Taylor S., De Ceniga M.V., Veller M., Vermassen F., Wang J., and Wang S.

Subjects
Global Vascular Guidelines, Management, Chronic Limb-Threatening Ischaemia
Abstract

The authors regret that the name of one of the co-author has been incorrectly spelt. Dr. Mauro Garguilo should have been spelt as “Mauro Gargiulo”. The authors would like to apologise for any inconvenience caused.

Published
2020

32. CO0001 MAVRILIMUMAB IMPROVES OUTCOMES IN SEVERE COVID-19 PNEUMONIA AND SYSTEMIC HYPER-INFLAMMATION

Author

De Luca, G., primary, Cavalli, G., additional, Campochiaro, C., additional, Della Torre, E., additional, Angelillo, P., additional, Tomelleri, A., additional, Boffini, N., additional, Tentori, S., additional, Mette, F., additional, Rovere-Querini, P., additional, Ruggeri, A., additional, D’aliberti, T., additional, Scarpelllini, P., additional, Landoni, G., additional, De Cobelli, F., additional, Paolini, J. F., additional, Zangrillo, A., additional, Tresoldi, M., additional, Trapnell, B. C., additional, Ciceri, F., additional, and Dagna, L., additional

Published
2020
Full Text
View/download PDF

38. P3349RHAPSODY: a pivotal phase 3 trial to assess efficacy and safety of rilonacept, an interleukin 1 alpha and beta blocker, in patients with recurrent pericarditis

Author

Imazio, M, primary, Klein, A, additional, Brucato, A, additional, Cremer, P, additional, Lewinter, M, additional, Abbate, A, additional, Lin, D, additional, Martini, A, additional, Beutler, A, additional, Chang, S, additional, Crugnale, S, additional, Fang, F, additional, Gervais, A, additional, Perrin, R, additional, and Paolini, J F, additional

Published
2019
Full Text
View/download PDF

39. Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer

Author

Nishio, M, Kim, D-W, Wu, Y-L, Nakagawa, K, Solomon, BJ, Shaw, AT, Hashigaki, S, Ohki, E, Usari, T, Paolini, J, Polli, A, Wilner, KD, Mok, T, Nishio, M, Kim, D-W, Wu, Y-L, Nakagawa, K, Solomon, BJ, Shaw, AT, Hashigaki, S, Ohki, E, Usari, T, Paolini, J, Polli, A, Wilner, KD, and Mok, T

Abstract

PURPOSE: Crizotinib has demonstrated superior progression-free survival (PFS) and objective response rates (ORRs) versus chemotherapy in previously treated and untreated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). We report the safety and efficacy of crizotinib in Asian subpopulations of two global phase III trials. MATERIALS AND METHODS: This analysis evaluated previously treated and untreated patients in two randomized, openlabel phase III trials of crizotinib versus chemotherapy in ALK-positive advanced NSCLC in second-line (PROFILE 1007) and first-line settings (PROFILE 1014). Efficacy and safety were analyzed by race in the intention-to-treat and "as-treated" populations for efficacy and safety endpoints, respectively. RESULTS: In previously treated (n=157) and untreated (n=157) Asian patients, PFS was statistically significantly longer with crizotinib versus chemotherapy (hazard ratio for PFS, 0.526; 95% confidence interval, 0.363 to 0.762; p < 0.001 and hazard ratio, 0.442; 95% confidence interval, 0.302 to 0.648; p < 0.001, respectively). Similar antitumor activity was seen in the non-Asian and overall populations. ORRs were statistically significantly higher with crizotinib versus chemotherapy in both Asian and non-Asian previously treated and untreated patients (p < 0.05). The most common treatment-emergent adverse events (any grade)with crizotinib were vision disorder, diarrhea, and nausea, which were observed at a comparable incidence across Asian and non-Asian populations, irrespective of previous treatment status. Most adverse events were mild to moderate in severity. CONCLUSION: These data, currently the only analysis showing Asian and non-Asian populations in the same study, support the efficacy and safety of crizotinib in Asian patients with previously treated or untreated ALK-positive advanced NSCLC.

Published
2018

40. Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study

Author

Gambacorti Passerini, C, Orlov, S, Zhang, L, Braiteh, F, Huang, H, Esaki, T, Horibe, K, Ahn, J, Beck, J, Edenfield, W, Shi, Y, Taylor, M, Tamura, K, Van Tine, B, Wu, S, Paolini, J, Selaru, P, Kim, T, Ahn, JS, Beck, JT, Edenfield, WJ, Van Tine, BA, Wu, SJ, Kim, TM, Gambacorti Passerini, C, Orlov, S, Zhang, L, Braiteh, F, Huang, H, Esaki, T, Horibe, K, Ahn, J, Beck, J, Edenfield, W, Shi, Y, Taylor, M, Tamura, K, Van Tine, B, Wu, S, Paolini, J, Selaru, P, Kim, T, Ahn, JS, Beck, JT, Edenfield, WJ, Van Tine, BA, Wu, SJ, and Kim, TM

Abstract

Crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK), MET, and ROS1, is approved for treatment of patients with ALK-positive or ROS1-positive advanced non-small-cell lung cancer (NSCLC). However, ALK rearrangements are also implicated in other malignancies, including anaplastic large-cell lymphoma and inflammatory myofibroblastic tumors (IMTs). In this ongoing, multicenter, single-arm, open-label phase 1b study (PROFILE 1013; NCT01121588), patients with ALK-positive advanced malignancies other than NSCLC were to receive a starting dose of crizotinib 250 mg twice daily. Primary endpoints were safety and objective responses based on Response Evaluation Criteria in Solid Tumors version 1.1 or National Cancer Institute International Response Criteria. Forty-four patients were enrolled (lymphoma, n=18; IMT, n=9; other tumors, n=17). The objective response rate was 53% (95% confidence interval [CI], 28-77) for lymphoma, with 8 complete responses (CRs) and 1 partial response (PR); 67% (95% CI, 30-93) for IMTs, with 1 CR and 5 PRs; and 12% (95% CI, 2-36) for other tumors, with 2 PRs in patients affected by colon carcinoma and medullary thyroid cancer, respectively. The median duration of treatment was almost 3 years for patients with lymphoma and IMTs, with 2-year progression-free survival of 63% and 67%, respectively. The most common treatment-related adverse events were diarrhea (45.5%) and vision disorders (45.5%), mostly grade 1. These findings indicate strong and durable activity of crizotinib in ALK-positive lymphomas and IMTs. The safety profile was consistent with the known safety profile of crizotinib even with long-term treatment

Published
2018

43. Approche multifactorielle pour la caractérisation de l’origine botanique des miels de Guyane

Author

Jiang, W., Robinson, J.C., Bereau, D., Battesti, M.J., Costa, J., Biercon, S., Paolini, J., RN, Sciences pour l'environnement (SPE), Centre National de la Recherche Scientifique (CNRS)-Université Pascal Paoli (UPP)-Centre National de la Recherche Scientifique (CNRS)-Université Pascal Paoli (UPP), and Renucci, Franck

Subjects
[CHIM.ORGA]Chemical Sciences/Organic chemistry, [CHIM.ORGA] Chemical Sciences/Organic chemistry, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2016

44. Pollen diversity and volatile variability of Corsican blossom honey

Author

Yang, Y., Battesti, M.J, Costa, J., Paolini, J., RN, Sciences pour l'environnement (SPE), Centre National de la Recherche Scientifique (CNRS)-Université Pascal Paoli (UPP)-Centre National de la Recherche Scientifique (CNRS)-Université Pascal Paoli (UPP), and Renucci, Franck

Subjects
[CHIM.ORGA]Chemical Sciences/Organic chemistry, [CHIM.ORGA] Chemical Sciences/Organic chemistry, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2016

45. Welcoming the green metabolomic era: supercritical fluid chromatography, tandem mass spectrometry, and molecular networking, as an efficient workflow to explore metabolome and isolate targeted compound

Author

Nothias-Scaglia, L-F, Boutet-Mercey, S., Cachet, X., de la Torre, H-E, Costa, J., Paolini, J., Bedoya, L-M, Alcami, J., Leyssen, P., Brunelle, A., Roussi, F., Touboul, D., Litaudon, M., RN, Sciences pour l'environnement (SPE), Centre National de la Recherche Scientifique (CNRS)-Université Pascal Paoli (UPP)-Centre National de la Recherche Scientifique (CNRS)-Université Pascal Paoli (UPP), Institut de Chimie des Substances Naturelles (ICSN), and Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)

Subjects
[CHIM.ORGA]Chemical Sciences/Organic chemistry, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2016

46. Discrimination of Corsican honeys by FTIR spectroscopy and chemometrics

Author

Lolliozi, A., Le Dreau, Y., Paolini, J., Costa, J., Dupuy, .N, Yang, Y., RN, Sciences pour l'environnement (SPE), and Centre National de la Recherche Scientifique (CNRS)-Université Pascal Paoli (UPP)-Centre National de la Recherche Scientifique (CNRS)-Université Pascal Paoli (UPP)

Subjects
[CHIM.ORGA]Chemical Sciences/Organic chemistry, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2016

47. Molecular networking of MS/MS as a tool to target antiviral diterpenoids from Corsican Euphorbia

Author

Esposito, M., Nothias-Scaglia, L-F, Leyssen, P., Roussi, F., Touboul, D., Costa, J., Paolini, J., Litaudon, M., RN, Sciences pour l'environnement (SPE), Centre National de la Recherche Scientifique (CNRS)-Université Pascal Paoli (UPP)-Centre National de la Recherche Scientifique (CNRS)-Université Pascal Paoli (UPP), Institut de Chimie des Substances Naturelles (ICSN), and Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)

Subjects
[CHIM.ORGA]Chemical Sciences/Organic chemistry, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2016

48. Qualification des miels de Corse : Diversité pollinique & variabilité chimique

Author

Yang, Y., Battesti, M.J, Costa, J., Paolini, J., RN, Sciences pour l'environnement (SPE), Centre National de la Recherche Scientifique (CNRS)-Université Pascal Paoli (UPP)-Centre National de la Recherche Scientifique (CNRS)-Université Pascal Paoli (UPP), and Renucci, Franck

Subjects
[CHIM.ORGA]Chemical Sciences/Organic chemistry, [CHIM.ORGA] Chemical Sciences/Organic chemistry, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2016

49. Chemical compositions of essential oils from Corsican propolis and Populus nigra var. italica buds

Author

Jiang, W., Yang, Y., Battesti, M.J, Costa, J., Paolini, J., RN, Sciences pour l'environnement (SPE), Centre National de la Recherche Scientifique (CNRS)-Université Pascal Paoli (UPP)-Centre National de la Recherche Scientifique (CNRS)-Université Pascal Paoli (UPP), and Renucci, Franck

Subjects
[CHIM.ORGA]Chemical Sciences/Organic chemistry, [CHIM.ORGA] Chemical Sciences/Organic chemistry, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2016

50. Volatile components as chemical markers of botanical origins of honey bee from Guiana

Author

Jiang, W., Robinson, J-C, Bereau, D., Battesti, M.J, Costa, J., Bercion, S., Paolini, J., Renucci, Franck, RN, Sciences pour l'environnement (SPE), and Centre National de la Recherche Scientifique (CNRS)-Université Pascal Paoli (UPP)-Centre National de la Recherche Scientifique (CNRS)-Université Pascal Paoli (UPP)

Subjects
[CHIM.ORGA]Chemical Sciences/Organic chemistry, [CHIM.ORGA] Chemical Sciences/Organic chemistry, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results